L'histoire naturelle du cancer de prostate métastatique

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S327, suppl. S7


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser






Tantivejkul K., Kalikin L.M., Pienta K.J. Dynamic process of prostate cancer metastasis to bone J Cell Biochem 2004 ;  91 : 706-717 [cross-ref]
Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 2008 ;  100 (16) : 1144-1154 [cross-ref]
D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 2004 ;  351 (2) : 125-135
D’Amico A.V. Screening for prostate carcinoma: prostate-specific antigen--friend or foe? Cancer 2005 ;  103 (5) : 881-883
Nelson WG, Saad F, Debruyne FMJ, et al. Prostate Cancer. 6th International Consultation on new developments in Prostate Cancer and Prostate diseases. 2006 6th edition. 309-345.
Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., Zincke H. The longterm clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 2003 ;  170 : 1872-1876 [cross-ref]
Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 2004 ;  171 (6pt1) : 2260-2264 [cross-ref]
D’Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 2003 ;  95 : 1376-1383
Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., Partin A.W. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 2005 ;  294 (4) : 433-439 [inter-ref]
Albertsen P.C., Hanley J.A., Penson D.F., Barrows G., Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort J Urol 2007 ;  177 (3) : 932-936 [cross-ref]
Luzzi K.J., MacDonald I.C., Schmidt E.E., et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases Am J Pathol 1998 ;  153 : 865-873 [cross-ref]
Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., Contag C.H. Animal models of bone metastasis Cancer 2003 ;  97 : 748-757 [cross-ref]
Vartanian R.K., Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason’s score, microvessel density, and epithelial cell proliferation Lab Invest 1995 ;  73 : 844-850
Brawer M.K., Deering R.E., Brown M., Preston S.D., Bigler S.A. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity Cancer 1994 ;  73 : 678-687 [cross-ref]
Bostwick D.G., Wheeler T.M., Blute M., et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies Urology 1996 ;  48 : 47-57 [inter-ref]
Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors in blood vessel formation Nature 2000 ;  407 : 242-248 [cross-ref]
Zeng Y., Opeskin K., Baldwin M.E., et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer Clin Cancer Res 2004 ;  10 : 5137-5144 [cross-ref]
Lin J., Lalani A.S., Harding T.C., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor Cancer Res 2005 ;  65 : 6901-6909 [cross-ref]
Bussemakers M.J., Van Bokhoven A., Tomita K., Jansen C.F., Schalken J.A. Complex cadherin expression in human prostate cancer cells Int J Cancer 2000 ;  85 : 446-450 [cross-ref]
Day M.L., Zhao X., Vallorosi C.J., et al. Ecadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway J Biol Chem 1999 ;  274 : 9656-9664 [cross-ref]
Tran N.L., Nagle R.B., Cress A.E., Heimark R.L. N-Cadherin expression in human prostate carcinoma cell lines: an epithelial–mesenchymal transformation mediating adhesion with stromal cells Am J Pathol 1999 ;  155 : 787-798 [cross-ref]
Bryden A.A., Hoyland J.A., Freemont A.J., Clarke N.W., Schembri Wismayer D., George N.J. E-cadherin and beta-catenin are downregulated in prostatic bone metastases BJU Int 2002 ;  89 (4) : 400-403 [cross-ref]
Sanda M.G., Restifo N.P., Walsh J.C., et al. Molecular characterization of defective antigen processing in human prostate cancer J Nat Cancer Inst 1995 ;  87 : 280-285 [cross-ref]
Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis Proc Natl Acad Sci U S A 2001 ;  98 : 3352-3357 [cross-ref]
Stoelcker B, Hafner M, Orosz P, Nieswandt B, Männel DN. Role of adhesion molecules and platelets in TNF-induced adhesion of tumor cells to endothelial cells: implications for experimental metastasis. J Inflamm 1995-1996;46(3):155-67.
Chay C.H., Cooper C.R., Gendernalik J.D., et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines Urology 2002 ;  60 : 760-765 [inter-ref]
Trikha M., Nakada M.T. Platelets and cancer: implications for antiangiogenic therapy Semin Thromb Hemost 2002 ;  28 : 39-44 [cross-ref]
Batson O.V. Function of vertebral veins and their role in spread of metastases Ann Surg 1940 ;  112 : 138-149 [cross-ref]
Al-Mehdi A.B., Tozawa K., Fisher A.B., Shientag L., Lee A., Muschel R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis Nat Med 2000 ;  6 : 100-102 [cross-ref]
Koeneman K.S., Yeung F., Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment Prostate 1999 ;  39 : 246-261 [cross-ref]
Zhau H.E., Li C.L., Chung L.W. Establishment of human prostate carcinoma skeletal metastasis models Cancer 2000 ;  88 (Suppl 12) : 2995-3001 [cross-ref]
Ritchie C.K., Andrews L.R., Thomas K.G., Tindall D.J., Fitzpatrick L.A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease Endocrinology 1997 ;  138 : 1145-1150 [cross-ref]
Cohen P., Peehl D.M., Lamson G., Rosenfeld R.G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells J Clin Endocrinol Metab 1991 ;  73 : 401-407 [cross-ref]
Arya M., Bott S.R., Shergill I.S., Ahmed H.U., Williamson M., Patel H.R. The metastatic cascade in prostate cancer Surg Oncol 2006 ;  15 (3) : 117-128 [cross-ref]
Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression Cancer Cell 2005 ;  8 : 393-406 [cross-ref]
Taylor B.S., Varambally S., Chinnaiyan A.M. A systems approach to model metastatic progression Cancer Res 2006 ;  66 : 5537-5539 [cross-ref]


© 2008  Elsevier Masson SAS. Tous droits réservés.